This document provides an overview of myelodysplastic syndrome (MDS). Key points include:
- MDS is a group of bone marrow disorders characterized by low blood cell counts, dysplastic changes in the bone marrow, and a risk of developing acute myeloid leukemia.
- It primarily affects older adults but can occur in younger patients as well. Risk factors include prior chemotherapy/radiation exposure, smoking, and certain genetic conditions.
- The disease involves malignant transformation of myeloid stem cells. Common genetic mutations impact DNA methylation and gene expression regulation.
- Patients present with anemia and related symptoms. Diagnosis involves blood and bone marrow tests showing dysplastic features. Prognosis depends on factors like blast percentage
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
"Impact of front-end architecture on development cost", Viktor TurskyiFwdays
I have heard many times that architecture is not important for the front-end. Also, many times I have seen how developers implement features on the front-end just following the standard rules for a framework and think that this is enough to successfully launch the project, and then the project fails. How to prevent this and what approach to choose? I have launched dozens of complex projects and during the talk we will analyze which approaches have worked for me and which have not.
Let's dive deeper into the world of ODC! Ricardo Alves (OutSystems) will join us to tell all about the new Data Fabric. After that, Sezen de Bruijn (OutSystems) will get into the details on how to best design a sturdy architecture within ODC.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
2. Introduction
• complex group of myeloid disorders characterized by
peripheral blood cytopenias
dysplasia in bone marrow hematopoietic cellular elements
Increased risk of development of AML
• Diagnosis is often supported by the presence of cytogenetic
alterations and, more recently, genetic mutations
3. EpidemiologyAnd Etiology
• Disease of aging ( median age - 70 yrs ). India –45yrs
• The incidence in U.S.- 4.1 per 1,00,000.
• Cause is not known
i) Therapy-related(t)-MDS , secondary to exposure to prior
chemo or radiation therapy
complex karyotypes
occur in younger patients
different patterns of disease evolution and cytogenetic
abnormalities
very poor prognosis
4. ii) Environmentalfactors
High benzene exposure (>3 ppm)
family history of hematopoietic cancer
Smoking
exposure to agricultural chemicals or solvents
Drinking wine reduced risk for all FABtypes by almost
50%
5. iii) Geneticsyndromes ass. with BM failure
Ribosomopathies - Diamond-Blackfan anemia
- Schwachman-Diamond syndrome
- Dyskeratosis congenita
- Cartilage hair hypoplasia
- Treacher Collins syndrome
Patients with Fanconi anemia are also at increased risk of
developing MDS (Runx1 mutation)
6. Rarefamilial syndromes
• Younger patients with thrombocytopenia or MDS should
be screened for Runx1 mutations
• Germline mutations in GATA-2 have also been involved in
a familial syndrome of MDS/AML,MonoMAC, and
lymphedema
• MonoMAC is an autosomal dominant syndrome associated
with monocytopenia; Band NKcell lymphopenia; and
mycobacterial, fungal, and viral infections, also associated
with pulmonary alveolar proteinosis
8. MDS:astemcell disorder
• malignant transformation of myeloid stem cell
• clones derived from an abnormal stem cell
Apoptosisin MDS
• increased apoptosis of haemopoietic precursors
• Presenceof cytopenias despite a typically hypercellular
bone marrow.
• For those patients undergoing leukaemic transformation,
the cytopenias arise due to maturation block of the
malignant cells
• more prominent in early MDS, such asRAand RARS,than
in advanced MDS with excess myeloblasts
9. IneffectiveHematopoiesis
• Colony forming capacities of pleuripotent stem cells and
their progeny are low or absent
• Lower level of GM-CSF, M-CSF,IL6 .IL 3
• CFU- GM less responsive to both G-CSF &GM-CSF
• More dramatic in pts with RAEBor RAEB–t
Angiogenesis
• Autocrine production of angiogenic molecules promotes
expansion of leukemic clone
• Vascular endothelial growth factor(VEGF) and its receptor
VEGFR-1And VEGFR-2is overexpressed
10. Immunologicalabnormalitiesin MDS
• Commonly encountered in MDS
• T-cell expansion
• B- cell alteration
• Particularly in cases of hypoplastic MDS
• • Acquired mutations in the PIG-A gene characteristic
of paroxysmal nocturnal haemoglobinuria (PNH) are
also encountered
11. Molecular Pathogenesis
The most frequent events are genes involved in control of
gene splicing and epigenetic regulators such as TET2or
ASXL1or EZH2.
• TET2
located on chromosome 4q24
DNAhydroxymethylation
mutations in TET2-abnormal DNAmethylation patterns
that could broadly impact gene expression patterns in
MDS
role in the homeostasis of hematopoietic stem cells
associated with response to azacitidine
12. • EZH2
located on chromosome 7 , Polycomb group family
control of epigenetic gene repression
EZH2 mutations in MDS inactivate the gene
poor prognosis
• specific molecular pathways may separate different subsets
of patients
• Bejar et al. separated pts into 2 major subgroups: those
with p53 mutations and complex cytogenetics, and those
without p53 mutations
Aberrant DNAMethylation Of PromoterCpg Islands-
common both in AMLand MDS
use of hypomethylating agents in MDS
patients with higher methylation scores had worse survival
13. Clinical Presentation& Complications
• not specific.
• Mostly diagnosed after peripheral blood examination
• suspected based on presence of one or more cytopenias
• symptoms of anemia, thrombocytopenia, fever, other
constitutional symptoms, or unexplained infections
• thorough evaluation to rule out other conditions that may
exclude MDS diagnosis
• diagnostic test always includes evaluation of the
morphology of a bone marrow specimen
• Cause of death - MDS-related with the most common
events being infection (38%), transformation to AML
(15%), and haemorrhage (13%
14. Diagnostic Evaluation
• Based on presence of dysplastic features on BMaspirate
Recommended -500 BMcells and 200 PBFcells
Dysplasia >10% of cells for each specific lineage
Erythroid dysplasia -sideroblasts,cellular vacuolization
Dysgranulopoiesis -alterations in size, nuclear
hypolobation, or hypersegmentation
Dysmegakaryopoiesis -micromegakaryocytes, hypolobation
or multinucleation
• Examination of a BM biopsy helps in evaluating cellularity
and the presence of significant fibrosis, making a diagnosis
of hypoplastic MDS versus aplastic anemia
16. F
ABclassificationin 1983
Five entities were defined:
• Refractory anemia (RA)
• RAwith ringed sideroblasts(RARS)
• RAwith excessblasts(RAEB)
• RAwith excessblasts in transformation (RAEB-t)
• Chronic myelomonocytic leukemia (CMML)
17. DIFFERENCESBETWEENWHO ANDFAB
• The WHO uses cytogenetic findings.
• RAEB-twas eliminated as it got included within
AML(>20%blasts).
• criteria proposed by the WHO replaced the prior FAB30%
blasts criteria,decreased to 20% by WHO
• CMMLwas removed and put in a new category of
myelodysplastic/myeloproliferative diseases.
• Adds the subtypes 5q syndrome and unclassifiable MDS.
• Recognizes the prognostic importance of %of bone
marrow blasts
18.
19.
20. • The most important assay,mandatory , is cytogenetic
analysis.There is no specific cytogenetic pattern diagnostic
of MDS
• both a diagnostic and a prognostic value
• In patients with profound marrow hypocellularity, the
presence of a cytogenetic alteration will differentiate
hypoplastic MDS from aplastic anemia
• Recent 5-subgroup classification , forms basis of IPSS-R
21. Flowcytometrycan help in the confirmation of MDS, and
specific phenotypes may have prognostic value.
• Presently , no panel diagnostic of MDS, can’t replace
morphologic examination
• may try to quantitate the percentage of blasts by
annotating the number of CD34+ cells.
• not an appropriate tool to estimate % of blasts, only
complementary
Newer genomic technologies are currently being
developed that allow the analysis of multiple genetic events
in MDS and other cancers.
• These include next-generation gene sequencing and
analysis of single nucleotide polymorphisms, not currently
integrated into clinical practice
22. MDS-RelatedSyndromes:CMMLand
OverlapMyelodysplasticMyeloproliferative Syndromes
• Chronic myelomonocytic leukemia - distinct WHOentity
• also includes BCR/ABLnegative CML,MDS/MPN
unclassified, juvenile myelomonocytic leukemia, and
potentially refractory anemia with ring sideroblasts and
thrombocytosis (RARS-T).
• Traditionally, CMML- subtype of MDS. IPSS- patients
with CMMLif the white cell count was less than 12 ×
103/L
• The natural history of patients with CMMLis distinct from
that of patients with classic MDS. Patients tend to have
higher frequency of Bsymptoms and extramedullary
manifestations of the disease. Tissue infiltration causing
hepatic or renal dysfunction is not uncommon.
23. • Diagnosis –
Persistent monocytosis (>1 ×109/L) without evidence of
BCR/ABLfusion genes or PDGFRalterations.
Blasts(promonocytes) < 20%and
dysplasia is routine, less pronounced than MDScategories
• CMML-1 andCMML-2 , based on the percentage of bone
marrow and peripheral blood blasts (CMML-1 < 10% bone
marrow blasts or < 5% in peripheral blood; CMML-2 with
more blasts)
• markers of myelomonocytic differentiation - CD33 and CD13
• Cytogenetic alterations occur as in other cases ofMDS
• presence of RASmutations - 40% of patients.
MDS/MPN unclassified (MDS/MPN-U) disorders - advent of
agents that inhibit JAK2,a common molecular alteration in
MPN that may explain the proliferative feature of the disease
25. HISTORY–
• Family history
• Exposure to Radiotherapy , Chemotherapy
• Recurrent Infections , Bleeding Gums
PHYSICALEXAMINATION
• Anemia
• 20% of pts have splenomegaly
• Unusual skin lesions –
Sweet syndrome, Granulocytic Sarcoma
• Autoimmune abnormalities (uncommon) - Seen in 14%of
the patients. Most common is cutaneous vasculitis.
26. • Stereotypical anomalies point to a constitutional syndrome
Short stature, abnormal thumbs - Fanconi anemia
Early graying - Telomeropathies
Cutaneous warts -GATA2 deficiency
LABORA
TORYSTUDY
CBC
• Threshold for cytopenia (IPSS)
Hb < 10 g/dl
Absolute neutrophil count< 1.8x 109 /L
Platelets < 100 x 109/L
• Anemia (MC),alone or as part of bi/pancytopenia
• Isolated neutropenia or thrombocytopenia is more unusual.
27. PBF
• RBCs- macrocytic
• Platelets - large and lackgranules.
• Neutrophils - hypo granulated; hypo segmented, ringed,or
abnormally segmented nuclei; contain Döhle bodies; and
may be functionally deficient
• Circulating myeloblasts usually correlate with marrow blast
BONEMARROW
• Usually normal or hypercellular
• 20% of cases:hypocellular to be confused with AA.
• No single characteristic feature of marrow morphology
distinguishes MDS, but the following are commonly
observed:
28.
29.
30.
31.
32.
33.
34. DIFFERENTIALDIAGNOSIS
• Vitamin B12 or folate deficiency
• Vitamin B6deficiency - Can be assessed by a
therapeutic trial of pyridoxine if the bone marrow
shows ringed sideroblast
• AML - WHO considers the presence of 20% blasts inthe
marrow as the criterion that separates AMLfromMDS
• Reactive Causes of Dysplasia –
HIV, recent cytotoxic therapy, alcoholism , recurrent
infections
• Congenital Sideroblastic Anaemia
• Paroxysmal Nocturnal Haemoglobinuria
• Toxins (lead &benzene) and Drugs ( Isoniazid )